Arecor Therapeutics plc
AREC.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £16 | £28 | £37 | £56 |
| - Cash | £2 | £3 | £3 | £5 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £15 | £25 | £35 | £51 |
| Revenue | £2 | £3 | £2 | £3 |
| % Growth | -34.5% | 53.3% | -31.3% | – |
| Gross Profit | £0 | -£1 | £2 | £3 |
| % Margin | 16.4% | -22% | 111% | 110.4% |
| EBITDA | -£2 | -£6 | -£5 | -£4 |
| % Margin | -120.9% | -183% | -228.2% | -140.2% |
| Net Income | -£3 | -£6 | -£5 | -£4 |
| % Margin | -125.2% | -183% | -232.6% | -138.6% |
| EPS Diluted | -0.066 | -0.15 | -0.15 | -0.13 |
| % Growth | 55.7% | 0% | -15.4% | – |
| Operating Cash Flow | -£1 | -£5 | -£4 | -£1 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£1 | -£5 | -£4 | -£1 |